整合素β_1在原发性肝癌中的表达及临床意义

Expression of integrin β_1 in primary hepatocellular carcinoma and its clinical significance

目的通过检测整合素β1在肝细胞癌组织中的表达,探讨其与原发性肝癌临床病理及预后的关系。方法 32例肝细胞癌手术标本,运用免疫组织化学S-P法,检测整合素β1在肝细胞癌组织中的表达,分析其与肿瘤临床病理资料和复发的关系。结果整合素β1在肝细胞癌中的阳性表达率为65.62%,阳性表达与患者性别、年龄等因素无关,而与肿瘤大小、分化程度有关。肿瘤直径越大,分化程度越低,阳性表达率越高。复发组的阳性表达率明显高于未复发组,差异有统计学意义(P<0.05)。结论整合素β1与原发性肝癌的发生、复发密切相关,有望作为原发性肝癌早期诊断和判断预后的重要指标。

Objective To detect the expression of integrin β1 in primary hepatocellular carcinoma（PHC）,and investigate its relationship with the clinical pathological characteristics or the prognosis of PHC.Methods The expressions of integrin β1 in 32 specimens of PHC were detected by S-P immunohistochemistry,and its relationship with tumor clinical pathology and recurrence was analyzed.Results The positive expression rate of integrin β1 in hepatocellular carcinoma was 65.62%.Its positive expression was significantly correlated with tumor size and tumor differentiation,but not with gender,age of patients.The greater the tumor diameter was and the lower the tumor differentiation was,the higher the expression rate was.The positive expression rate of integrin β1 was significantly higher in patients with recurrence than those without recurrence（P〈0.05）.Conclusion The expressions of integrin β1 is closely related to the occurrence and recurrence of PHC,and may serve as a significant marker in the early diagnosis and prognosis of PHC.